Dysfunction of the upper and lower airways frequently coexist, and they appear to share key
elements of pathogenesis. Data from epidemiologic studies indicate that nasal symptoms …

Five biologicals have been approved for severe eosinophilic asthma, a well‐recognized
phenotype. Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, …

Background Omalizumab (Xolair ® ) is a recombinant humanized monoclonal anti‐IgE antibody
with proven efficacy in patients with moderate‐to‐severe and severe persistent allergic (…

Background Many patients with asthma have uncontrolled disease despite treatment with
inhaled glucocorticoids. One potential cause of the variability in response to treatment is …

Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody
that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and …

Background Tezepelumab is a human monoclonal antibody that blocks thymic stromal
lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma. The …

Background: A recombinant humanized anti-IgE mAb, omalizumab, forms complexes with
free IgE, blocking its interaction with mast cells and basophils; as a consequence, it might be …

Background In some patients with moderate-to-severe asthma, particularly those with
noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the efficacy …

Background Dupilumab, a fully human anti-interleukin-4 receptor α monoclonal antibody,
inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation…

Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by IgE
hyperproduction and eosinophilic inflammation. The anti-IgE antibody, omalizumab, has …